The DOI matches its Crossref record; 73 of the 73 references it cites were found in a registry or an index.
From Fibrosis to Sclerosis
Open accessAbstract
Progression of diabetic nephropathy to end-stage kidney disease is mediated by a host of processes, but none is as important as the gradual, inexorable scarring of the renal glomerulus, known as glomerulosclerosis. Hence, a host of studies over the decades have attempted to elucidate the molecular mechanisms that lead to this chronic sclerosing condition so that effective therapies and preventative strategies can be developed. Over the past several years, the general understanding of the pathogenic factors that lead to this important feature of diabetic nephropathy has improved considerably. Glomerulosclerosis in diabetic nephropathy is caused by accumulation of extracellular matrix (ECM) proteins in the mesangial interstitial space, resulting in fibrosis manifested by either diffuse or nodular changes (1). The most common matrix proteins detected are collagen types I, III, and IV and fibronectin (2). These accumulate both due to increased synthesis by mesangial cells and reduced degradation by mesangial matrix metalloproteinases (3). Over 20 years ago, Mauer et al. (4) established the clear link between mesangial matrix expansion and progression of diabetic kidney disease by demonstrating that measures of mesangial expansion strongly predicted the clinical manifestations of diabetic nephropathy. Since then, the critical charge to investigators has been to elucidate the mechanisms that promote glomerulosclerosis in diabetic nephropathy. In this brief perspective, we will review pathogenic processes that appear to be critical in the development of diabetic glomerulosclerosis, emphasizing newer findings and insights. During the 1990s, a general consensus emerged about major signaling mechanisms involved in stimulating mesangial cell synthesis of ECM proteins (Fig. 1). In this consensus view, high extracellular glucose induces an increase in glucose uptake via increased expression of the facilitative glucose transporter GLUT1 (5,6). The resultant enhancement in glucose metabolic flux leads to activation of a number of metabolic pathways that result in increased advanced …
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Eremina, V., Sood, M., Haigh, J., Nagy, A., Lajoie, G., Ferrara, N., Gerber, H.-P., Kikkawa, Y., Miner, J. H., & Quaggin, S. E. (2003) · Journal of Clinical Investigation · doi:10.1172/jci17423 · Cited by 1,313
Structural-functional relationships in diabetic nephropathy.
Mauer, S. M., Steffes, M. W., Ellis, E. N., Sutherland, D. E., Brown, D. M., & Goetz, F. C. (1984) · Journal of Clinical Investigation · doi:10.1172/jci111523 · Cited by 1,209
Podocyte loss and progressive glomerular injury in type II diabetes.
Pagtalunan, M. E., Miller, P. L., Jumping-Eagle, S., Nelson, R. G., Myers, B. D., Rennke, H. G., Coplon, N. S., Sun, L., & Meyer, T. W. (1997) · Journal of Clinical Investigation · doi:10.1172/jci119163 · Cited by 1,088
Advanced Glycosylation End Products in Patients with Diabetic Nephropathy
Makita, Z., Radoff, S., Rayfield, E. J., Yang, Z., Skolnik, E., Delaney, V., Friedman, E. A., Cerami, A., & Vlassara, H. (1991) · New England Journal of Medicine · doi:10.1056/nejm199109193251202 · Cited by 918
Mouse Models of Diabetic Nephropathy
Brosius, F. C., Alpers, C. E., Bottinger, E. P., Breyer, M. D., Coffman, T. M., Gurley, S. B., Harris, R. C., Kakoki, M., Kretzler, M., Leiter, E. H., et al. (2009) · Journal of the American Society of Nephrology · doi:10.1681/asn.2009070721 · Cited by 895
Self-citationYamamoto, T., Nakamura, T., Noble, N. A., Ruoslahti, E., & Border, W. A. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.5.1814 · Cited by 830
Wharram, B. L., Goyal, M., Wiggins, J. E., Sanden, S. K., Hussain, S., Filipiak, W. E., Saunders, T. L., Dysko, R. C., Kohno, K., Holzman, L. B., et al. (2005) · Journal of the American Society of Nephrology · doi:10.1681/asn.2005010055 · Cited by 737
Kato, M., Zhang, J., Wang, M., Lanting, L., Yuan, H., Rossi, J. J., & Natarajan, R. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0611192104 · Cited by 699
Extracellular Matrix Metabolism in Diabetic Nephropathy
Mason, R. M., & Wahab, N. A. (2003) · Journal of the American Society of Nephrology · doi:10.1097/01.asn.0000065640.77499.d7 · Cited by 655
Ziyadeh, F. N., Sharma, K., Ericksen, M., & Wolf, G. (1994) · Journal of Clinical Investigation · doi:10.1172/jci117004 · Cited by 597
Cited by
Pathologic Classification of Diabetic Nephropathy
Tervaert, T. W. C., Mooyaart, A. L., Amann, K., Cohen, A. H., Cook, H. T., Drachenberg, C. B., Ferrario, F., Fogo, A. B., Haas, M., de Heer, E., et al. (2010) · Journal of the American Society of Nephrology · doi:10.1681/asn.2010010010 · Cited by 1,690
Thomas, M. C., Brownlee, M., Susztak, K., Sharma, K., Jandeleit-Dahm, K. A. M., Zoungas, S., Rossing, P., Groop, P.-H., & Cooper, M. E. (2015) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2015.18 · Cited by 1,230
Epigenetics and epigenomics in diabetic kidney disease and metabolic memory
Kato, M., & Natarajan, R. (2019) · Nature Reviews Nephrology · doi:10.1038/s41581-019-0135-6 · Cited by 600
The cardio-renal-metabolic connection: a review of the evidence
Marassi, M., & Fadini, G. P. (2023) · Cardiovascular Diabetology · doi:10.1186/s12933-023-01937-x · Cited by 386
Diabetic nephropathy—emerging epigenetic mechanisms
Kato, M., & Natarajan, R. (2014) · Nature Reviews Nephrology · doi:10.1038/nrneph.2014.116 · Cited by 318
Metadata
- Authors
- Qian, Y., Feldman, E., Pennathur, S., Kretzler, M., & Brosius, F. C.
- Venue
- Diabetes
- Publisher
- American Diabetes Association
- Published
- 2008-06-01
- Volume
- 57
- Issue
- 6
- Pages
- 1439-1445
- ISSN
- 0012-1797 (ISSN-L)
- 1939-327X
- OpenAlex
- W2113965152
- Cited by
- 325
- References
- 73
- FWCI
- 11.28
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: From Fibrosis to Sclerosis. https://app.cochat.ai/papers/10.2337/db08-0061
- The paper
- Qian, Y., Feldman, E., Pennathur, S., Kretzler, M., & Brosius, F. C. (2008). From Fibrosis to Sclerosis. Diabetes. https://doi.org/10.2337/db08-0061
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.